HomeCompareGNHAY vs PEP

GNHAY vs PEP: Dividend Comparison 2026

GNHAY yields 5.29% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNHAY wins by $6.10M in total portfolio value
10 years
GNHAY
GNHAY
● Live price
5.29%
Share price
$38.39
Annual div
$2.03
5Y div CAGR
62.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.25M
Annual income
$4,849,407.89
Full GNHAY calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — GNHAY vs PEP

📍 GNHAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNHAYPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNHAY + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNHAY pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNHAY
Annual income on $10K today (after 15% tax)
$449.27/yr
After 10yr DRIP, annual income (after tax)
$4,121,996.71/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, GNHAY beats the other by $4,068,080.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNHAY + PEP for your $10,000?

GNHAY: 50%PEP: 50%
100% PEP50/50100% GNHAY
Portfolio after 10yr
$3.20M
Annual income
$2,456,419.20/yr
Blended yield
76.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

GNHAY
No analyst data
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNHAY buys
0
PEP buys
0
No recent congressional trades found for GNHAY or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNHAYPEP
Forward yield5.29%3.66%
Annual dividend / share$2.03$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR62.6%40.4%
Portfolio after 10y$6.25M$144.7K
Annual income after 10y$4,849,407.89$63,430.49
Total dividends collected$6.10M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: GNHAY vs PEP ($10,000, DRIP)

YearGNHAY PortfolioGNHAY Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$11,559$859.42$10,854$514.44+$705.00GNHAY
2$13,878$1,509.66$11,982$758.21+$1.9KGNHAY
3$17,604$2,754.33$13,526$1,136.44+$4.1KGNHAY
4$24,146$5,309.21$15,727$1,741.93+$8.4KGNHAY
5$36,902$11,066.02$19,012$2,750.28+$17.9KGNHAY
6$65,185$25,700.29$24,173$4,514.44+$41.0KGNHAY
7$138,737$68,988.48$32,789$7,793.80+$105.9KGNHAY
8$371,577$223,128.79$48,258$14,354.51+$323.3KGNHAY
9$1,305,722$908,134.35$78,586$28,686.63+$1.23MGNHAY
10$6,246,530$4,849,407.89$144,688$63,430.49+$6.10MGNHAY

GNHAY vs PEP: Complete Analysis 2026

GNHAYStock

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

Full GNHAY Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this GNHAY vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNHAY vs SCHDGNHAY vs JEPIGNHAY vs OGNHAY vs KOGNHAY vs MAINGNHAY vs MOGNHAY vs PMGNHAY vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.